Best mode for treating hard cataracts

Article

The "multiburst" mode of bimanual microincision phacoemulsification machines is unsuitable for treating cataracts with a nuclear density of Grade 3 and above, according to study results published in the July 2008 issue of Clinical & Experimental Ophthalmology.

The "multiburst" mode of bimanual microincision phacoemulsification machines is unsuitable for treating cataracts with a nuclear density of Grade 3 and above, according to study results published in the July 2008 issue of Clinical & Experimental Ophthalmology.

Liu Yizhi, MD, PhD of the Zhongshan Ophthalmic Center at Sun Yat-sen University, Guangzhou, China and colleagues assessed the effects on "hard" cataracts of the "multiburst" and "shortburst" settings of the Sovereign phaco machine (AMO) in comparison to the settings on the Whitestar technology platform (AMO).

The differences between the three groups were statistically significant. The ultrasonic power was highest for the Whitestar, followed by Sovereign's shortpulse and then the multiburst setting. The multiburst setting had the highest ultrasonic power release time, effective phaco time and rate of endothelial cell loss; the group displaying the lowest levels of these variables was the Whitestar group. In the multiburst group, there was also one case of wound burn and three eyes displaying abnormal fluctuations in the anterior chamber depth.

Based on these data, the research team concluded that, while Sovereign's multiburst mode was an unreliable method of performing this type of surgery, Whitestar technology had the best results of the study and offers an acceptable alternative.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.